AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27813716 — intervention group
Group type: COMPARATOR
Intervention: Nonirradiated mini-implants (control group)
Number of subjects: 10
Study 27813716 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LLLT and control)
Number of subjects: 10
Study 25946686 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX Score II (SSII) recommendation for CABG or PCI
Number of subjects: 202
Study 25946686 — intervention group
Group type: COMPARATOR
Intervention: Heart Team (HT) decision to recommend CABG
Number of subjects: 202
Study 25946686 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for PCI irrespective of HT decision
Number of subjects: 202
Study 24023757 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pravastatin for 3.2 years
Number of subjects: 5804
Study 24023757 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5804
Study 21816077 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine hepcidin concentrations at six and twenty-four hours after CPB in AKI-free patients (N = 91)
Number of subjects: 100
Study 21816077 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine hepcidin adjusted to urine creatinine at six hours after CPB
Number of subjects: 100
Study 21816077 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma hepcidin
Number of subjects: 100
Study 19435164 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school programs
Number of subjects: 0
Study 19435164 — intervention group
Group type: COMPARATOR
Intervention: Comparison groups
Number of subjects: 0
Study 16418021 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL of bupivacaine (150 mg)
Number of subjects: 63
Study 16418021 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL of ropivacaine (150 mg)
Number of subjects: 63
Study 16418021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 150 mg, morphine 4 mg, and ketorolac 30 mg in normal saline (total volume 30 mL)
Number of subjects: 63
Study 12925453 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg pretreatment, 75 mg/d for 1 year)
Number of subjects: 2116
Study 12925453 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4-MET statin (atorvastatin, lovastatin, simvastatin, cerivastatin) with clopidogrel
Number of subjects: 2116
Study 12925453 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-CYP3A4-MET statin (pravastatin, fluvastatin) with clopidogrel
Number of subjects: 2116
Study 12925453 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment, 75 mg/d for 1 month)
Number of subjects: 2116
Study 12925453 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy with statins
Number of subjects: 2116
Study 10714533 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy (SMT) for 2 months (maximum of 16 treatments)
Number of subjects: 127
Study 10714533 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 127
Study 8655877 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (20 mg) administered three times a day for 5 days
Number of subjects: 47
Study 8655877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 1421065 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 30
Study 1421065 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 30
Study 6386095 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy (HSV)
Number of subjects: 137
Study 6386095 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy and pyloroplasty (TVP)
Number of subjects: 137
Study 30251616 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual placement and support (IPS) for 6 months in addition to treatment as usual (TAU)
Number of subjects: 146
Study 30251616 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 146
Study 29074815 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 120
Study 29074815 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Care + Hyperbaric Oxygen Therapy (SC+HBOT)
Number of subjects: 120
Study 25965708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning
Number of subjects: 0
Study 25965708 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred stent implantation in the infarct-related lesion
Number of subjects: 0
Study 25965708 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of the culprit lesion only
Number of subjects: 0
Study 25965708 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (primary angioplasty and complete revascularization)
Number of subjects: 0
Study 24818336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 200,000 IU ulinastatin in 100 mL of 0.9% saline given over one hour every 12 hours for 5 days
Number of subjects: 135
Study 24818336 — intervention group
Group type: COMPARATOR
Intervention: Placebo in 100 mL of 0.9% saline given over one hour every 12 hours for 5 days
Number of subjects: 135
Study 24818336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 200,000 IU ulinastatin
Number of subjects: 135
Study 24818336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 21769200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg intravenously (i.v.)
Number of subjects: 100
Study 21769200 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ondansetron 4 mg and dexamethasone 4 mg i.v.
Number of subjects: 100
Study 19151299 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200-1600 mg
Number of subjects: 0
Study 19151299 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam 15 mg
Number of subjects: 0
Study 19151299 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of meloxicam and gabapentin
Number of subjects: 0
Study 19151299 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study 17986361 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway (appropriate use of practice guidelines, supplies of drugs and ancillary services, new organization and procedures, patient education)
Number of subjects: 424
Study 17986361 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway
Number of subjects: 424
Study 17986361 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 424
Study 15146374 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.4 mg daily for 12 weeks
Number of subjects: 69
Study 11354394 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily
Number of subjects: 106
Study 11354394 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2% 3 times daily
Number of subjects: 106
Study 7955995 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-045 (400 mg daily)
Number of subjects: 14
Study 7955995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3599276 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial femoral-popliteal veins (SF-PVs)
Number of subjects: 120
Study 3599276 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed saphenous veins (RSVs)
Number of subjects: 120
Study 3599276 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 120
Study 29602433 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock-Instructor (e-learning tool)
Number of subjects: 33
Study 27166340 — intervention group
Group type: EXPERIMENTAL
Intervention: Generate group estimated their overall movement time then received knowledge of results of their actual movement time
Number of subjects: 36
Study 27166340 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice group selected their perceived movement time from a list of three alternatives
Number of subjects: 36
Study 27166340 — intervention group
Group type: COMPARATOR
Intervention: Control group did not self-report their perceived movement time and received knowledge of results of their actual movement time on every trial
Number of subjects: 36
Study 25613105 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified TAU + Therapeutic Education System (TES)
Number of subjects: 506
Study 25613105 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 506
Study 23582867 — intervention group
Group type: EXPERIMENTAL
Intervention: TF‐CBT (n = 24)
Number of subjects: 52
Study 23582867 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (n = 28)
Number of subjects: 52
Study 20854930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 120
Study 20854930 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 120
Study 20854930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20854930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline+tDCS
Number of subjects: 120
Study 19070269 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective opioid withdrawal scale during detoxification (18 measurements)
Number of subjects: 200
Study 17212098 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly hepatic arterial infusion (HAI) chemotherapy with 5-FU (1500 mg) for 8 weeks
Number of subjects: 0
Study 17212098 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion group with identical total dosage of 5-FU
Number of subjects: 0
Study 17212098 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly HAI chemotherapy
Number of subjects: 0
Study 17212098 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI chemotherapy using a W spiral catheter
Number of subjects: 0
Study 14616329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 microg x kg(‐1) h(‐1))
Number of subjects: 43
Study 14616329 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 43
Study 10652688 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual outreach
Number of subjects: 2000
Study 10652688 — intervention group
Group type: COMPARATOR
Intervention: Health education classes
Number of subjects: 2000
Study 10652688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing follow-up counseling
Number of subjects: 2000
Study 10652688 — intervention group
Group type: COMPARATOR
Intervention: Screening alone
Number of subjects: 2000
Study 9332680 — intervention group
Group type: EXPERIMENTAL
Intervention: Zorubicin 325 mg/m2, day 1 (Group A)
Number of subjects: 80
Study 9332680 — intervention group
Group type: COMPARATOR
Intervention: Zorubicin 250 mg/m2, day 1 and cisplatin 30 mg/m2, days 2-5 (Group B)
Number of subjects: 80
Study 8877187 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical beclomethasone (100 micrograms spray to each nasal cavity twice daily for 3 weeks)
Number of subjects: 8
Study 8877187 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline treatment for 3 weeks)
Number of subjects: 8
Study 3772840 — intervention group
Group type: EXPERIMENTAL
Intervention: TM plus home exercise training
Number of subjects: 210
Study 3772840 — intervention group
Group type: EXPERIMENTAL
Intervention: TM plus medically supervised gym training
Number of subjects: 210
Study 3772840 — intervention group
Group type: COMPARATOR
Intervention: TM without formal exercise program
Number of subjects: 210
Study 3772840 — intervention group
Group type: COMPARATOR
Intervention: Control group (seen only at six months post MI)
Number of subjects: 210
Study 29763339 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐shaped distal triceps tendon repair technique
Number of subjects: 24
Study 29763339 — intervention group
Group type: EXPERIMENTAL
Intervention: Knotless suture‐bridge repair technique
Number of subjects: 24
Study 29763339 — intervention group
Group type: COMPARATOR
Intervention: Transosseous cruciate repair technique
Number of subjects: 24
Study 26004120 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses
Number of subjects: 24
Study 26004120 — intervention group
Group type: COMPARATOR
Intervention: Sham foot orthoses
Number of subjects: 24
Study 23567372 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip fracture surgery
Number of subjects: 142
Study 22260337 — intervention group
Group type: COMPARATOR
Intervention: Nabilone (4 mg)
Number of subjects: 14
Study 22260337 — intervention group
Group type: COMPARATOR
Intervention: Nabilone (6 mg)
Number of subjects: 14
Study 22260337 — intervention group
Group type: COMPARATOR
Intervention: Nabilone (8 mg)
Number of subjects: 14
Study 22260337 — intervention group
Group type: COMPARATOR
Intervention: Dronabinol (10 mg)
Number of subjects: 14
Study 22260337 — intervention group
Group type: COMPARATOR
Intervention: Dronabinol (20 mg)
Number of subjects: 14
Study 22260337 — intervention group
Group type: COMPARATOR
Intervention: Nabilone (2 mg)
Number of subjects: 14
Study 22260337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (4 mg), Nabilone (6 mg), Nabilone (8 mg)
Number of subjects: 14
Study 22260337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 14
Study 19594293 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 504
Study 19594293 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 70 mg once weekly
Number of subjects: 504
Study 18088568 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea in air
Number of subjects: 16
Study 18088568 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea with face immersion
Number of subjects: 16
Study 18088568 — intervention group
Group type: COMPARATOR
Intervention: Resting eupneic control
Number of subjects: 16
Study 15832630 — intervention group
Group type: EXPERIMENTAL
Intervention: Speeded responding errors
Number of subjects: 0
Study 15832630 — intervention group
Group type: EXPERIMENTAL
Intervention: Confusability errors
Number of subjects: 0
Study 15832630 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest intervention
Number of subjects: 0
Study 15832630 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 signal-detection measure
Number of subjects: 0
Study 12678347 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 100
Study 12678347 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 100
Study 10650898 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron plus dexamethasone (100 mg dolasetron i.v. + 20 mg dexamethasone)
Number of subjects: 210
Study 10650898 — intervention group
Group type: COMPARATOR
Intervention: Dolasetron alone (100 mg dolasetron i.v.)
Number of subjects: 210
Study 10650898 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron plus dexamethasone
Number of subjects: 210
Study 10650898 — intervention group
Group type: COMPARATOR
Intervention: Dolasetron alone
Number of subjects: 210
Study 10650898 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron plus dexamethasone and Dolasetron alone
Number of subjects: 210
Study 8672376 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 1 mg kg‐1
Number of subjects: 40
Study 8672376 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 40
Study 1586706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 94
Study 1586706 — intervention group
Group type: COMPARATOR
Intervention: Antithymocyte globulin (ATG) with prednisone (PDN)
Number of subjects: 94
Study 3838725 — intervention group
Group type: EXPERIMENTAL
Intervention: molsidomine
Number of subjects: 31
Study 3838725 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study 30762479 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit/stand workstation
Number of subjects: 18
Study 30762479 — intervention group
Group type: COMPARATOR
Intervention: Traditional (sit) workplace
Number of subjects: 18
Study 29853426 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate artery embolization
Number of subjects: 0
Study 27882007 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 on d1) and Cisplatin (25 mg/m2 on d1-3)
Number of subjects: 50
Study 27882007 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (25 mg/m2 on d1-3) and Fluorouracil (400 mg/m2)
Number of subjects: 50
Study 27882007 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed and Cisplatin
Number of subjects: 50
Study 27882007 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and Fluorouracil
Number of subjects: 50
Study 25375047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure vessel sealing system
Number of subjects: 33
Study 25375047 — intervention group
Group type: COMPARATOR
Intervention: Linking and electrocautery
Number of subjects: 33
Study 22866912 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaped snacks (heart, hands, animals)
Number of subjects: 21
Study 22866912 — intervention group
Group type: COMPARATOR
Intervention: Normal snacks (round, square)
Number of subjects: 21
Study 22866912 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian children
Number of subjects: 21
Study 22866912 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian children
Number of subjects: 21
Study 22866912 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who had not eaten breakfast or lunch prior to the snack
Number of subjects: 21
Study 20421357 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (60 units)
Number of subjects: 48
Study 20421357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 48
Study 18931202 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA) - 10 mg/kg IV bolus after induction followed by 1 mg/kg/hr maintenance infusion
Number of subjects: 151
Study 18931202 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 151
Study 18931202 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 151
Study 15764775 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc insufflation (TTI)
Number of subjects: 482
Study 15764775 — intervention group
Group type: COMPARATOR
Intervention: Talc slurry (TS)
Number of subjects: 482
Study 12185445 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (5000 IU/ml)
Number of subjects: 99
Study 12185445 — intervention group
Group type: COMPARATOR
Intervention: Sodium Chloride (0.9%)
Number of subjects: 99
Study 12185445 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (200 mg/ml)
Number of subjects: 99
Study 10705625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg/day
Number of subjects: 120
Study 10705625 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg/day
Number of subjects: 120
Study 8938880 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine nasal spray (0.5 mg/ml)
Number of subjects: 22
Study 8938880 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 22
Study 1769132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg orally) + naloxone (3 mg/h infusion over 5 hours)
Number of subjects: 20
Study 1769132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg orally)
Number of subjects: 20
Study 1769132 — intervention group
Group type: COMPARATOR
Intervention: Fenfluramine (60 mg orally) + saline infusion
Number of subjects: 20
Study 1769132 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo + saline infusion
Number of subjects: 20
Study 6870998 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate running (n = 36)
Number of subjects: 64
Study 6870998 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (n = 28)
Number of subjects: 64
Study 31553889 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional exercise group performing four sets to failure
Number of subjects: 151
Study 31553889 — intervention group
Group type: EXPERIMENTAL
Intervention: One-repetition maximum (1RM) group performing a 1RM test
Number of subjects: 151
Study 31553889 — intervention group
Group type: COMPARATOR
Intervention: Time-matched non-exercise control group
Number of subjects: 151
Study 30196900 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g sucrose
Number of subjects: 28
Study 30196900 — intervention group
Group type: COMPARATOR
Intervention: 0.8 g aspartame (placebo)
Number of subjects: 28
Study 27382812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal Ketamine (0.1mg/kg) added to bupivacaine (10mg)
Number of subjects: 90
Study 27382812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal Fentanyl (25 µg) added to bupivacaine (10mg)
Number of subjects: 90
Study 27382812 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.5 ml distilled water) added to bupivacaine (10mg)
Number of subjects: 90
Study 25782321 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of phospholipid nanoparticles
Number of subjects: 0
Study 25782321 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 22851566 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m(2) every 3 weeks for four cycles (P3)
Number of subjects: 4554
Study 22851566 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg/m(2) weekly for 12 cycles (P1)
Number of subjects: 4554
Study 22851566 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m(2) every 3 weeks for four cycles (D3)
Number of subjects: 4554
Study 22851566 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 35 mg/m(2) weekly for 12 cycles (D1)
Number of subjects: 4554
Study 20482765 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Self-Monitoring of Blood Glucose (SMBG)
Number of subjects: 504
Study 20482765 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (Active Control Group)
Number of subjects: 504
Study 20482765 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured SMBG
Number of subjects: 504
Study 20482765 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care
Number of subjects: 504
Study 17655758 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based treatment by occupational physicians (OPs)
Number of subjects: 0
Study 17655758 — intervention group
Group type: COMPARATOR
Intervention: Usual care with minimal OP involvement and easy access to a psychologist
Number of subjects: 0
Study 16278088 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 239
Study 16278088 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 239